← All Travere Therapeutics, INC filings

Travere Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
TVTX
Travere Therapeutics, INC
DEF: Travere Therapeutics 2026 Annual Meeting Proxy
Travere Therapeutics has issued its 2026 proxy statement detailing proposals for director elections, an equity incentive plan amendment, and executive compensation advisory votes.
NASDAQ
TVTX
Travere Therapeutics, INC
DEFA14A: Travere Therapeutics to Hold Annual Stockholders Meeting on May 15, 2025
Travere Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on May 15, 2025, to vote on director elections, equity incentive plan amendments, executive compensation, and auditor ratification.
NASDAQ
TVTX
Travere Therapeutics, INC
DEF: Travere Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Travere Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on May 15, 2025, featuring proposals including director elections, equity incentive plan amendments, executive compensation approval, and auditor ratification.
NASDAQ
TVTX
Travere Therapeutics, INC
DEFA14A: Travere Therapeutics to Hold Annual Stockholders Meeting on May 8, 2024
Travere Therapeutics will hold its annual stockholders meeting on May 8, 2024, to vote on director elections, equity incentive plan amendments, executive compensation, and auditor ratification.
NASDAQ
TVTX
Travere Therapeutics, INC
DEF 14A: Travere Therapeutics Seeks Stockholder Approval for Equity Incentive Plan Expansion and Director Elections at Upcoming Annual Meeting
Travere Therapeutics is holding its annual meeting on May 8, 2024, to vote on director elections, an equity incentive plan amendment, executive compensation, and auditor ratification.